Stock Events

Stock Events

Cabaletta Bio 

$3.12
143
-$0.26-7.69% Friday 20:00
+$0.06+1.92%Friday 23:51After hours

Statistics

Day High
3.13
Day Low
3.11
52W High
4.23
52W Low
1.4
Volume
86,755
Avg. Volume
-
Mkt Cap
528.98M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.73
-0.59
-0.45
-0.32
Expected EPS
-0.316924
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-167.86MNet Income

Analyst Ratings

16.50Average Price Target
The highest estimate is 30.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CABA. It's not an investment recommendation.
NVIDIA
23
NVDA
Rocket Lab
22
RKLB
Tesla
18
TSLA
Amazon
18
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to the development of treatments for autoimmune diseases, directly competing with Cabaletta Bio's focus on engineered T cell therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a leading developer of CRISPR gene editing therapies, potentially targeting similar autoimmune and other diseases as Cabaletta Bio.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the CRISPR gene editing space, focusing on delivering transformative genetic treatments that could overlap with Cabaletta Bio's therapeutic areas.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T cell therapies, which could be used in similar applications to Cabaletta Bio's autologous T cell therapies, making them direct competitors.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is developing programmed cellular immunotherapies, including NK and T-cell therapies, which could compete with Cabaletta Bio's engineered T cell approaches for autoimmune diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies but is expanding into gene therapies, which could potentially compete with Cabaletta Bio's approach to treating autoimmune diseases.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its broad interest in biopharmaceuticals, including investments in gene therapy and immunology, represents a potential competitor across multiple areas of Cabaletta Bio's interest due to its scale and breadth of research.

About

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Show more...
CEO
Steven A. Nichtberger
Employees
158
Country
United States
ISIN
US12674W1099

Listings

MX
MX
CABA.MX
XNAS
US
CABA
BOATS
BOATS
CABA.BOATS

0 Comments

Share your thoughts

FAQ

What is Cabaletta Bio stock price today?▼
The current price of CABA is $3.12 USD — it has decreased by -7.69% in the past 24 hours. Watch Cabaletta Bio stock price performance more closely on the chart.
What is Cabaletta Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cabaletta Bio stocks are traded under the ticker CABA.
Is Cabaletta Bio stock price growing?▼
CABA stock has risen by +0.65% compared to the previous week, the month change is a +16.42% rise, over the last year Cabaletta Bio has showed a +115.17% increase.
What is Cabaletta Bio market cap?▼
Today Cabaletta Bio has the market capitalization of 528.98M
When is the next Cabaletta Bio earnings date?▼
Cabaletta Bio is going to release the next earnings report on November 05, 2026.
What were Cabaletta Bio earnings last quarter?▼
CABA earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.37 USD resulting in a +8.82% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cabaletta Bio revenue for the last year?▼
Cabaletta Bio revenue for the last year amounts to 0 USD.
What is Cabaletta Bio net income for the last year?▼
CABA net income for the last year is -167.86M USD.
How many employees does Cabaletta Bio have?▼
As of August 31, 2026, the company has 158 employees.
In which sector is Cabaletta Bio located?▼
Cabaletta Bio operates in the Health & Wellness sector.
When did Cabaletta Bio complete a stock split?▼
Cabaletta Bio has not had any recent stock splits.
Where is Cabaletta Bio headquartered?▼
Cabaletta Bio is headquartered in PHILADELPHIA, United States.